Purpose: The aims of this study were to examine a national database to assess codeine poisonings before and after the new guidance for pharmacists while also evaluating rates of codeine prescriptions following the introduction of restrictions on supply.
prescription opioid related overdoses in the USA increased by a similar factor from 2000 to 2014 and reached 18 893 in 2014. 5 The degree of concern regarding misuse and abuse of prescription analgesics is evident by the intervention of the US Surgeon General with the "Turn the Tide Rx." 6 The extent to which these opioid analgesics are misused is difficult to quantify in countries with non-prescription access. [7] [8] [9] This is due to a lack of reliable data and the refusal of pharmaceutical companies to release sales data because of its commercial sensitivity. 1, 3, 10 However, there is no doubt that there is significant misuse of non-prescription opioids, most notably codeine containing products. [11] [12] [13] This misuse has consequences for the physical and mental health of the individual, and may result in a poisoning episode.
Codeine poisonings are among the top five most frequently referred to the National Poisonings Information Service in the United Kingdom. 14 There is also a considerable risk of adverse effects from the second active ingredient in codeine containing combinations. 15, 16 In 2010, the Pharmaceutical Society of Ireland (PSI) issued guidance framing previous legislation in relation to the supply of codeine containing products. 17 The guidance was entitled "Non-Prescription 
18,19
The National Poisons Information Centre (NPIC) assists health care professionals and the public with enquiries relating to poisonings.
Reports to the centre have been previously shown to be sensitive to new legislative restrictions on paracetamol supply. 20 The study aims were to (a) examine NPIC data to assess poisoning rates related to codeine products before and after the issuance of the guidance and (b) evaluate trends in codeine prescriptions before and after the restriction of supply of OTC alternatives. The evidence resulting from the study may aid policymakers to decide on appropriate levels of regulatory restrictions on the supply of codeine to the public. Chemical (ATC) classification code. 23 The classification was used to analyse reimbursement rates of paracetamol products and opium alkaloid-based products (eg, oxycodone).
| Statistics analysis
NPIC data were annualised, divided into cases involving nonprescription and prescription products, and plotted for comparison.
Descriptive statistics were performed for the study period. The source
KEY POINTS
• In Ireland, the extent of opioid misuse is challenging to accurately quantify, so that surrogate markers such as poisoning rates may provide useful public health information.
• During the study period, 2005 to 2016, the number of codeine-related poisonings reduced annually with a 53% reduction in total (both prescription and nonprescription).
• There was a 62% reduction in poisonings involving nonprescription codeine preparations with a 33% annual decrease from 2010 to 2011 following the new national guidance to pharmacists on the supply of codeine in 2010.
• On analysis of pharmacy claims data for opioid analgesics, the rate of reimbursed prescriptions for low dose co-codamol did not increase.
• There was no evident increase in the rate of more potent alternatives reimbursed.
and circumstance of case reports pre and post 2010 were analysed using the Chi-squared test providing the relative risk. The beginning of 2010 and 2011 was chosen as a transition points for annualised data. Segmented regression analyses were used to analyse the NPIC data over the study period using the chosen cut-offs. 24 The effect of the intervention was quantified in terms of the change in level (β2 coefficient) and slope (β3 coefficient) at the time points above. Further analysis of quarterly data was performed with a transition point at the end of quarter 2, 2010 (Q2 2010). As more time points were available, the quarterly NPIC data were further analysed using segmental regression with a negative binomial model for rates reflecting the method used for HSE-PCRS data (see below). As a supplementary analysis, the mean of the monthly reports for the year prior to the first of July 2010 was compared with that for the year after using the Independent t test. 25 Analysis was performed using Microsoft Excel and SPSS software version 20 (IBM Corp, Armonk, New York).
For the HSE-PCRS pharmacy claims, rates of patients reimbursed per 1000 eligible GMS population in each year were calculated for the study. The data were analysed using segmented regression analyses, including a level and slope change, with a negative binomial model for rates (using a log offset for the eligible population). Quarterly, data were used to determine whether the change in rate over the quarters differed for the medicines under study before compared with after the chosen cut-off using incidence rate ratios (IRR) and 95% confidence intervals (95% CI). SAS statistical software v9.3 was used (SAS Institute Inc Cary, North Carolina).
| Ethics
The study was referred to the Beaumont Hospital Research Ethics
Committee. As the data used were fully anonymised, the approval process was not necessary. The study was registered with the Beaumont Hospital Clinical Governance Department. Ethical approval for the PCRS component of this study was not required as all data were anonymised.
| RESULTS
The NPIC received n = 1851 calls regarding codeine containing products from 2005 to 2016. The mean age of the case subjects was 23 years old (standard deviation +/−18.1). Of those with an age recorded (n = 1845), 38% were less than 18 years and 3% were 65 or older. Of those with a gender recorded (n = 1833), the majority were female (63%).
Codeine containing products available OTC were implicated in 1346 cases (73%). The combination most frequently associated with the reported poisonings, at 30% of cases, contained paracetamol and codeine (500 mg/8 mg). Fifty-one percent of the cases were referred from a hospital, 30% from a general practitioner/family doctor, and involving co-codamol increased three fold. The TGA has since taken the decision to make these medications prescription only from February 2018. 28 Our research shows a contrasting effect in terms of poisonings reported. Although the decreasing trend was not sustained, the rate of codeine poisoning reports remains stable at a lower level that at any time previously.
In October 2014, the US Drugs Enforcement Agency enforced the rescheduling of products containing hydrocodone restricting their availability. 25 In a study of the reports of opioid poisonings to the Texas Poison Centre Network, there was a 28% decrease in poisonings involving hydrocodone when comparing the 6 months before and after the rescheduling. However, those involving codeine increased by 176%. There were also smaller but significant increases in the cases involving oxycodone and tramadol. The authors suggest that prescribers chose products, which have less prescribing restrictions for their patients. In our study, there was no increase in the reimbursement of co-codamol products containing 30 mg of codeine or those of more potent opioids (Figure 4) .
A recent UK study of pharmacists' perception of non-prescription co-codamol misuse noted that 88% of pharmacists knew of customers regularly purchasing co-codamol. 29 While the potential misuse of nonprescription codeine products is well recognised in Ireland, 30 ,31 the PSI guidance had gained considerable media attention. 32, 33 Professional and public opinion regarding the change in practice brought about by the guidance were reported in the national media. 34 Social media reaction since the guidance refers to the rigorous questioning process patients underwent. 35 Pharmacist intervention is well described as a trigger for those misusing codeine to seek medical support. 36 Nielsen et al have reported that codeine consumers sought medical attention because of greater pharmacist intervention following regulatory change in Australia in 2010. 37 Other qualitative research from the UK also affirms the point. 38 The PSI guidance may have prompted greater vigilance among professionals and the public with regard to codeine supply and misuse.
The guidance coincided with the increase in the proportion of codeine poisoning reported by primary care professionals and pharmacists to the NPIC. In a cross-sectional study of codeine product prescribing in the UK, practitioners noted an increase in patients seeking codeine products on prescription following new restrictions. 31 Although our study cannot identify changes in requests made to primary care practitioners for codeine, there was no increase in the prescribing of these codeine products or potential substitutes. 
| Strengths and limitations
Strengths of this study include the high frequency of referrals to the NPIC allowing an analysis. It is the only such service in the country.
The data are reliably recorded by toxicology experts. The product or substance involved was carefully recorded. This data were compared with a large national pharmacy claims database. This enabled analysis of the effect of guidance on trends in the reimbursement and prescription of codeine products, which adds a novel aspect to this study.
Limitations of the study include the failure to capture all relevant poisoning cases. This is because of the referral of cases to the NPIS in the UK between 22.00 and 08.00. These calls account for approximately 15% to 20% of total calls to the NPIC. Indeed, even during operating hours, not all poisonings may be reported to the NPIC, particularly those that are less serious in nature. The poisoning case rates do not capture chronic abuse and misuse of codeine containing analgesics. The analysis of the annualised data was limited by the number of time points available so that IRR were only derived for the quarterly data. In terms of the HSE-PCRS pharmacy claims data, this is only representative of patients with access to community drug schemes, which subsidise medication costs. These patients are more likely to be female, from deprived backgrounds or elderly patients when compared with the general population. As such, the claims data are likely to over represent the actual prescribing rates for the Irish population. 41 The start of the study period for the PCRS was limited by changes to coding of products in 2006.
| CONCLUSION
This study has found a decrease in reported poison cases involving non-prescription codeine products in 2011. This was following the publication and implementation of guidance for pharmacists when dispensing non-prescription codeine products. This decrease was consistent with reductions in previous years, although of a larger magnitude.
The decrease may have been related to a restriction of nonprescription codeine products. The rate of pharmacy claims for the co-codamol products or alternative analgesics did not increase, suggesting there was no substitution with prescribed co-codamol products. This study will inform policymakers when considering strategies to mitigate the increasing risk of opioid misuse.
